Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma-A retrospective multicenter study

2015 ◽  
Vol 87 (7) ◽  
pp. 1199-1206 ◽  
Author(s):  
Naoki Harada ◽  
Naoki Hiramatsu ◽  
Tsugiko Oze ◽  
Tomohide Tatsumi ◽  
Norio Hayashi ◽  
...  
2014 ◽  
Vol 18 (1) ◽  
pp. 65-68 ◽  
Author(s):  
Müzeyyen Gönül ◽  
Seray Külcü Çakmak ◽  
Nimet Özcan ◽  
Işil Deniz Oǧuz ◽  
Esra Özhamam

Background: Pegylated interferon-α combined with ribavirin is the current standard treatment for chronic hepatitis C virus infection. During interferon and ribavirin therapy, both local and generalized mucocutaneous adverse reactions have been reported. Erythema annulare centrifugum induced by this therapy regimen has not been reported previously. Case Report: A 29-year-old woman was referred to our clinic for a 1-week history of slightly pruritic annular erythematous eruptions on the lower extremities and hands. The eruptions had first occured on the hands 3 to 4 days after pegylated interferon-α-2a plus ribavirin combination therapy for hepatitis C virus infection. Histopathologic examination supported the diagnosis of erythema annulare centrifugum. The lesions completely regressed within 2 weeks after the cessation of treatment but recurred on similar localizations within 24 hours with the same therapy. It was thought that erythema annulare centrifugum was induced by pegylated interferon-α-2a plus ribavirin combination therapy. Conclusion: Erythema annulare centrifugum is considered an inflammatory skin disease with unknown etiology. It is thought to represent a hypersensitivity reaction to some triggering factors, including infections, immunologic disorders, malign neoplasms, foods, pregnancy, and drugs. We report the first case of erythema annulare centrifigum induced by pegylated interferon-α-2a plus ribavirin combination therapy.


Sign in / Sign up

Export Citation Format

Share Document